Trial Profile
Phase II trial of docetaxel plus ramucirumab combination therapy in patients with advanced EGFR gene mutation positive advanced stage non-squamous cell nonsmall cell lung cancer (HSR 1701)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2019
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary) ; Pegfilgrastim
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jan 2018 New trial record